NEW YORK (GenomeWeb) – Canadian biopharmaceutical firm BiOasis last week announced that it has thrown its hat into the RNAi therapeutics ring and aims to advance an siRNA-based drug into Phase I testing before the end of next year.

While BiOasis hasn't made a final decision on what will be its first RNAi candidate, the firm recently presented limited data showing that its delivery technology could successfully carry siRNAs targeting Nox4, a gene involved in the generation of reactive oxygen species, across the blood-brain barrier (BBB).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.